Cognitive decline after treatment can significantly affect daily living in survivors of non-Hodgkin’s lymphoma (NHL). Many individuals who have undergone chemotherapy, radiation, or combined treatments for NHL report persistent difficulties with memory, attention, processing speed, problem-solving skills, and learning new…
Stem cell banks play a crucial and multifaceted role in advancing research and treatment for non-Hodgkin’s lymphoma (NHL), particularly by supporting stem cell transplantation and innovative cellular therapies. These banks collect, store, and provide hematopoietic stem cells—cells capable of regenerating…
Younger patients with non-Hodgkin’s lymphoma (NHL) can indeed benefit from different therapies compared to older patients, largely due to differences in biology, treatment tolerance, and long-term health considerations. The approach to treating NHL is not one-size-fits-all; age plays a crucial…
Non-Hodgkin’s lymphoma (NHL) research addresses fertility preservation by focusing on understanding how cancer treatments affect reproductive health and developing strategies to protect or restore fertility before, during, and after therapy. Since many treatments for NHL, such as chemotherapy and radiation,…
Genomic sequencing has emerged as a powerful tool to personalize care for patients with non-Hodgkin’s lymphoma (NHL), a diverse group of blood cancers originating in lymphocytes. By analyzing the complete genetic makeup of a patient’s lymphoma cells, genomic sequencing reveals…
Digital health plays a transformative role in monitoring treatment response for non-Hodgkin’s lymphoma (NHL) by enabling continuous, real-time, and personalized tracking of patient status through advanced technologies. This approach integrates medical imaging, wearable devices, mobile apps, and artificial intelligence (AI)…
Rural patients can significantly benefit from decentralized non-Hodgkin’s lymphoma (NHL) research programs because such programs bring specialized care, clinical trials, and advanced treatment options closer to their communities, overcoming many barriers that rural populations typically face. Decentralization means shifting research…
Non-Hodgkin’s lymphoma (NHL) research addresses disparities in minority populations by focusing on understanding the unique challenges these groups face, improving access to care, and tailoring treatments to their specific needs. Researchers recognize that racial and ethnic minorities often experience higher…
Telemedicine has the potential to significantly expand access to clinical trials for patients with non-Hodgkin’s lymphoma (NHL), a diverse group of blood cancers affecting the lymphatic system. Traditionally, participation in NHL clinical trials has been limited by geographic, logistical, and…
Patient-reported outcomes (PROs) play a crucial and increasingly recognized role in non-Hodgkin’s lymphoma (NHL) research by providing direct insight into how patients experience their disease and its treatment. Unlike traditional clinical measures such as tumor size or survival rates, PROs…